Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12058968 | 0.90 | LMNA (0.47) | LMNACYP2C19HRH4RAB9ANPC1 | |
| SCHEMBL6923306 | 0.90 | RAB9A (0.43) | LMNACYP2C19MAOBTGFBR1HRH4 | |
| SCHEMBL12059068 | 0.88 | LMNA (0.50) | LMNACYP2C19RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6920958 | 0.84 | GRM2 (0.45) | TGFBR1GRM2BCL2A1 | |
| SCHEMBL6921795 | 0.84 | GRM2 (0.46) | RAB9ANPC1GRM2BCL2A1SMN1; SMN2 | |
| SCHEMBL6922513 | 0.84 | RXFP1 (0.45) | LMNACYP2C19RAB9AGRM2SMN1; SMN2 | |
| SCHEMBL6920781 | 0.84 | LMNA (0.48) | LMNACYP2C19RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6923346 | 0.84 | GRM5 (0.42) | LMNACYP2C19MAOB | |
| SCHEMBL6923330 | 0.82 | KDM4E (0.58) | LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6923502 | 0.82 | BCL2A1 (0.37) | MAOBRAB9ANPC1GRM2BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | LMNA 4613/4885CYP2C19 4711/4885MAOB 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.